HEALTHY EXTRACTS INC. acquires Gummy USA LLC (2025)

Deal facts

Buyer: HEALTHY EXTRACTS INC.
Target: Gummy USA LLC
Deal value: Not disclosed
Announced: 2 October 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares

Sources

SEC_EDGAR_8K SEC_EDGAR_8K

What we know

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

2 updates

30 Sept 2025CompletedClosed
HEALTHY EXTRACTS INC. completes acquisition of Gummy USA LLC
Item 1.01 Entry into a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. Acquisition of Gummy USA LLC On July 19, 2025, we entered into a Membership Interest Purchase Agreement (the “MIPA”) with Gummy USA LLC (“GUSA”) and its sole-member, Donald Swanson (“Swanson”), pursuant to which we acquired one-hundred percent (100%) of the outstanding membership interes
Source
19 Jul 2025CompletedClosed
HEALTHY EXTRACTS INC. completes acquisition of Gummy USA LLC
Item 1.01 Entry into a Material Definitive Agreement. Acquisition of Gummy USA LLC On July 19, 2025, we entered into a Membership Interest Purchase Agreement (the “MIPA”) with Gummy USA LLC (“GUSA”) and its sole-member, Donald Swanson (“Swanson”), pursuant to which we acquired one-hundred percent (100%) of the outstanding membership interests of GUSA, which is now our wholly-owned subsidiary. As c
Source

OpinionExit Mode editorial

We see a clear signal in the completed acquisition of Gummy USA LLC by Healthy Extracts Inc. announced on 2 October 2025. This is a strategic move within the healthcare sector, executed entirely through a share exchange. The fact that the deal is already completed suggests both parties moved with speed and certainty, likely having resolved any material commercial or regulatory hurdles before the announcement. In the US market, a pure share consideration deal often implies a strong alignment of long-term interests between the buyer and the target, as the founders and key stakeholders remain exposed to the future performance of the combined entity.

For the SME founder reading this, the structure of the transaction offers a specific lesson on how strategic buyers value growth. By choosing shares over cash, Healthy Extracts Inc. has effectively deferred the full cost of the acquisition and tied the payout to their own future success. This mechanism shifts the risk profile significantly. If the combined business struggles to integrate the gummy brand or fails to meet market expectations, the value of the consideration drops. Conversely, if the strategic fit delivers the anticipated synergies, the upside remains uncapped. This is distinct from a cash deal where the seller walks away with a fixed sum regardless of future integration success.

The absence of a disclosed value in the public record is not unusual for private US transactions, yet it highlights the importance of understanding the underlying mechanics. When a deal closes without a headline price, the focus must shift to the terms of the share exchange and the governance structure that follows. Founders must scrutinise the change-of-control covenants and the voting rights attached to the new shares. In the healthcare sector, where regulatory scrutiny from bodies like the FDA is constant, maintaining operational independence post-close can be difficult. The board composition and decision-making rights will define whether the target retains its identity or becomes a mere division.

You should review your current cap table and identify which shareholders hold the power to approve a share-based exit. If you are considering a strategic sale, insist on a detailed breakdown of the share exchange ratio and the specific vesting schedules attached to any retained equity before signing a term sheet.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More strategic acquisition deals More from HEALTHY EXTRACTS INC.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Not statedCompletedHealthcare

Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited

Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…

Buyer: Circle Health Holdings Limited
Target: CHC Healthcare Holdings Limited
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

15 October 2026CompletedHealthcare

Cronos Group Inc. to acquire CanAdelaar B.V.

Cronos Group Inc. has agreed to acquire CanAdelaar B.V. in a strategic acquisition within the healthcare sector. The Canadian buyer will purchase the Dutch target for a…

Buyer: Cronos Group Inc.
Target: CanAdelaar B.V.
Deal value: EUR 57,500,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Netherlands deals

13 October 2026CompletedHealthcare

Alaunos Therapeutics, Inc. to acquire Velaris Therapeutics, Inc.

Alaunos Therapeutics, Inc. has agreed to acquire Velaris Therapeutics, Inc. in a strategic acquisition. The transaction was announced on 13 October 2026 and was complete…

Buyer: Alaunos Therapeutics, Inc.
Target: Velaris Therapeutics, Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

11 October 2026Firm intentionHealthcare

STERIS Corporation to acquire Xodus Medical, Inc.

STERIS Corporation has agreed to acquire Xodus Medical, Inc. in a strategic transaction valued at two billion US dollars. The healthcare deal was announced on 11 October…

Buyer: STERIS Corporation
Target: Xodus Medical, Inc.
Deal value: USD 2,100,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

9 October 2026CompletedHealthcare

Hepion Pharmaceuticals, Inc. to acquire Gravitas Life Sciences, LLC

Hepion Pharmaceuticals, Inc. has agreed to acquire Gravitas Life Sciences, LLC in a strategic acquisition. The transaction, valued at 4.25 million US dollars, was comple…

Buyer: Hepion Pharmaceuticals, Inc.
Target: Gravitas Life Sciences, LLC
Deal value: USD 4,250,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

Buyer history